Post by peryannie4 on May 26, 2021 7:17:47 GMT -5
Bosutinib specifically is a dual SRC/ABL1 TKI with minimal inhibitory activity against KIT and PDGFR used in order to treat adult patients with chronic, accelerated or blast phase Ph+ CML with resistance or intolerance to prior therapy. The bosutinib tablets are available in the strength 100mg and 500mg, which should be taken as exactly prescribed by a healthcare practitioner.
In patients taking bosutinib, common adverse reactions may include nausea, rash, vomiting,
thrombocytopenia, diarrhea, and abdominal pain.
In patients taking bosutinib, common adverse reactions may include nausea, rash, vomiting,
thrombocytopenia, diarrhea, and abdominal pain.